eRAM
encyclopedia of Rare Disease Annotation for Precision Medicine
| Disease | cystic fibrosis |
| Symptom | C0854135|pseudomonas aeruginosa infection |
| Sentences | 28 |
| PubMedID- 22084956 | Economic burden of pseudomonas aeruginosa infection in patients with cystic fibrosis. |
| PubMedID- 24194436 | Tobramycin inhalation powder: a review of its use in the treatment of chronic pseudomonas aeruginosa infection in patients with cystic fibrosis. |
| PubMedID- 19996339 | Treatment of early pseudomonas aeruginosa infection in patients with cystic fibrosis: the elite trial. |
| PubMedID- 24995163 | Liposomal ciprofloxacin has been further developed by aradigm corporation for pseudomonas aeruginosa infections in patients with cystic fibrosis and non-cystic fibrosis bronchiectasis. |
| PubMedID- 25417708 | Levofloxacin inhalation solution for the treatment of chronic pseudomonas aeruginosa infection among patients with cystic fibrosis. |
| PubMedID- 23680696 | Hydrogen cyanide concentrations in the breath of adult cystic fibrosis patients with and without pseudomonas aeruginosa infection. |
| PubMedID- 22401602 | Challenges with current inhaled treatments for chronic pseudomonas aeruginosa infection in patients with cystic fibrosis. |
| PubMedID- 24068273 | pseudomonas aeruginosa infection in patients with cystic fibrosis: scientific evidence regarding clinical impact, diagnosis, and treatment. |
| PubMedID- 26438797 | pseudomonas aeruginosa infections persist in patients with cystic fibrosis (cf) and drive lung disease progression. |
| PubMedID- 20137079 | Feasibility study to inform the design of a randomised controlled trial to eradicate pseudomonas aeruginosa infection in individuals with cystic fibrosis. |
| PubMedID- 25027418 | pseudomonas aeruginosa infection is a hallmark of lung disease in cystic fibrosis. |
| PubMedID- 22762867 | Comparison of two treatment regimens for eradication of pseudomonas aeruginosa infection in children with cystic fibrosis. |
| PubMedID- 21883670 | Initial pseudomonas aeruginosa infection in patients with cystic fibrosis: characteristics of eradicated and persistent isolates. |
| PubMedID- 24091166 | Background: inhaled tobramycin therapy has been shown to be efficacious in clinical trials for the eradication of initial pseudomonas aeruginosa infection in children with cystic fibrosis (cf). |
| PubMedID- 21942255 | All approved antimicrobial agents for administration by inhalation are indicated for pseudomonas aeruginosa infections in patients with cystic fibrosis. |
| PubMedID- 23910799 | pseudomonas aeruginosa infections are commonly associated with cystic fibrosis, pneumonias, neutropenia and burns. |
| PubMedID- 22857271 | Regulatory aspects of phase 3 endpoints for new inhaled antibiotics for cystic fibrosis patients with chronic pseudomonas aeruginosa infections. |
| PubMedID- 22496040 | Background: accelerated lung function decline in cystic fibrosis (cf) is associated with mucoid pseudomonas aeruginosa infection. |
| PubMedID- 24510624 | Colistimethate sodium dry powder for inhalation: a review of its use in the treatment of chronic pseudomonas aeruginosa infection in patients with cystic fibrosis. |
| PubMedID- 20729233 | Background: initial pulmonary pseudomonas aeruginosa infection in patients with cystic fibrosis (cf) is currently treated with intensive antibiotic therapy. |
| PubMedID- 26534255 | Adherence to inhaled antibiotics for the treatment of chronic pseudomonas aeruginosa infection in patients with cystic fibrosis: a systematic literature review. |
| PubMedID- 23152277 | Objectives: to compare biofilm antimicrobial susceptibility testing-driven therapy to conventional antimicrobial susceptibility testing-driven therapy in the treatment of pseudomonas aeruginosa infection in people with cystic fibrosis. |
| PubMedID- 20941353 | Such within-species polymicrobial infection have been reported mainly in chronic and/or open infections (pseudomonas aeruginosa infections of lung in cystic fibrosis patients and of burn wounds , staphylococcus epidermidis joint prosthesis infection , lung tuberculosis , . |
| PubMedID- 24737619 | Why is a healthy person protected from pseudomonas aeruginosa infections, while individuals with cystic fibrosis or damaged epithelium are particularly susceptible to this opportunistic pathogen. |
| PubMedID- 23802816 | Rationale: the efficacy of inhaled tobramycin on chronic pseudomonas aeruginosa infections in patients with cystic fibrosis (cf) has been established in clinical trials. |
| PubMedID- 20442386 | Context: azithromycin is recommended as therapy for cystic fibrosis (cf) patients with chronic pseudomonas aeruginosa infection, but there has not been sufficient evidence to support the benefit of azithromycin in other patients with cf. |
| PubMedID- 21893650 | Comparative efficacy and safety of 4 randomized regimens to treat early pseudomonas aeruginosa infection in children with cystic fibrosis. |
| PubMedID- 20837573 | Early pseudomonas aeruginosa infection in individuals with cystic fibrosis: is susceptibility testing justified. |
Page: 1